Marinus Pharmaceuticals, Inc. shareholders who have suffered significant losses are urged to contact Robbins LLP regarding their rights in the MRNS Class Action Lawsuit.

Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) securities…

Read More: https://www.businesswire.com/news/home/20240614535690/en/